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ABSTRACT 
 
Background 
Diabetes confers a 2-fold excess risk of atherosclerotic cardiovascular disease (ASCVD), yet 
predicting individual risk remains challenging. The effect of total microvascular disease 
burden on ASCVD risk among individuals with diabetes is unknown.  
 
Methods  
A population-based cohort of patients with type 2 diabetes from the UK Clinical Practice 
Research Datalink was studied (n=48 367). We used multivariable Cox models to estimate 
the hazard ratios for ASCVD (fatal and non-fatal events of myocardial infarction or ischemic 
stroke) associated with cumulative burden of retinopathy, nephropathy and peripheral 
neuropathy among individuals with no history of cardiovascular disease at baseline.  
 
Results 
During a median follow-up of 5.5 years, 2689 (5.6%) individuals experienced a cardiovascular 
event. Significant associations were observed for ASCVD individually for retinopathy, 
peripheral neuropathy, and nephropathy after adjustment for established risk factors. The 
hazard ratios (with 95% confidence intervals) were 1.16 (1.06-1.27), (1.26, 1.16-1.38), and 
(1.49, 1.36-1.62), respectively. For individuals with one, two or three microvascular disease 
states versus none, the multivariable-adjusted hazard ratios for ASCVD were 1.30 (1.16-
1.47), 1.64 (1.45-1.87) and 2.24 (1.91-2.64), respectively. The hazard ratios for fatal 
cardiovascular events and hospitalization for heart failure were similar. For ASCVD, 
measures of risk discrimination showed significant improvement when microvascular disease 
was added to models. 
 
Conclusions 
The cumulative burden of microvascular disease significantly impacts the risk of future 
cardiovascular disease among individuals with type 2 diabetes. Given the prevalence of 
diabetes globally, further work to understand the mechanisms behind this association and 
strategies to mitigate this excess risk are warranted.  
 
 
 
 
 
 
 
 
  
INTRODUCTION 
 
Diabetes confers a 2-fold excess risk of cardiovascular disease1 and substantial premature 
mortality from cardiovascular causes.2 However, individuals with diabetes are not 
automatically considered as a coronary heart disease (CHD) risk equivalent and many 
guidelines now recommend absolute risk assessment prior to considering lipid modification 
therapy.3 Predicting individual risk remains challenging and external validation of available 
risk algorithms in diabetic populations show moderate performance at best,4 highlighting the 
need for cheap and routinely available measures that identify those with higher absolute risk 
over and above established factors considered in contemporary risk algorithms. 
 
Various microvascular disease states have been reported to be associated with risk of 
vascular disease, including cardiac autonomic neuropathy (CAN),5, 6 retinopathy,7, 8 
nephropathy,9 and peripheral neuropathy.10 Despite frequently co-existing, robust population 
data evaluating the effect of cumulative microvascular disease burden on cardiovascular risk 
in diabetes is absent. The aim of this study was to investigate whether microvascular disease 
states alone or in unison are independently associated with atherosclerotic cardiovascular 
disease (ASCVD), and furthermore to compare any strength of association with conventional 
risk factors used in current risk equations. To assess this relationship, we used routine 
healthcare data from a large population-based cohort of individuals with type 2 diabetes free 
from CVD at baseline, with approximately 259 686 person years of follow up and 2689 first 
cardiovascular events.   
 
METHODS 
Data sources and cohort 
The Clinical Practice Research Datalink (CPRD) comprises data on individuals from over 600 
practices in England, providing a representative UK primary care population.11, 12 CPRD 
contains information on anthropometric measurements, clinical diagnoses, laboratory tests 
and prescription data, coded with the Read Clinical Coding system. Information on 
retinopathy, nephropathy and peripheral neuropathy has been routinely collected in UK 
primary care following the introduction of a pay for performance initiative, the Quality and 
Outcomes Framework,13 in April 2004, which is linked to the National Institute for Health and 
Care Excellence (NICE) guidance on standards of care for patients in the UK including 
appropriate frequency of screening and risk factor control for those with chronic diseases.14 
 
Individual patient data were linked across three datasets: the CPRD for demographic 
characteristics and, Hospital Episode Statistics (HES) and the Office for National Statistics 
(ONS) for the outcomes of interest. The HES are the English National Health Service 
administrative dataset and contain information on every hospital admission including 
diagnostic data, recorded as International Classification of Diseases, 10th revision (ICD-10), 
and procedural data based on the Office of Population, Census, and Surveys, version 4 
(OPCS-4) codes. The ONS provide individual mortality records including cause of death (ICD-
10).  
 
The study start date was 1 April 2008 to allow for 4 years of quality data on microvascular 
disease status among participants. The data extract provided by CPRD included data on 48 
367 individuals aged 18 years and over with type 2 diabetes and complete information on the 
presence or absence of three microvascular diseases: retinopathy, nephropathy and 
peripheral neuropathy. Individuals were screened for the presence of diabetes using 
established criteria,15 and classified in accordance with methods described previously.16 
Diabetes was defined by fasting plasma glucose ≥126 mg per deciliter (7.0 mmol per liter), 
random plasma glucose ≥200 mg per deciliter (11.1 mmol per liter) or the use of glucose 
lowering medications, based on recommendations from the American Diabetes Association.15, 
17 In brief, classification of T2DM was performed according to the following criteria: specific 
diagnostic code for T2DM (Read code C10F; ICD-10 code E11) with no contradictory code; 
and patients with a diagnosis of diabetes at ≥35 years of age with no insulin prescription 
within 1 year of diagnosis. Validation study of electronic health records using this approach 
corrected miscoding of diabetes type in between 6-8% of cases.16 We excluded individuals 
with a prior history of any cardiovascular disease.   
 
Definition of baseline variables 
Anthropometric measurements and numerical data, including systolic and diastolic blood 
pressure, glycated hemoglobin, and cholesterol values were derived by taking the mean of 
the three most recent values in the 12 months prior to the study start date. In cases where 
three values were unavailable, the mean of two values was calculated. Values recorded more 
than 12 months prior to the study start were not considered. Smoking status was stratified into 
groups of never smoked, previously smoked and currently smoking at entry into the study. 
Code lists used to define microvascular disease states were developed in accordance with 
published guidance,18, 19 and are provided in the Supplementary Appendix 1-3).  
 
Outcome ascertainment 
The follow-up period extended to the study end: either December 2014, the date of patient 
transfer from an included practice, or death. The primary outcome was the time to first major 
atherosclerotic cardiovascular event (an a priori composite of fatal and non-fatal events of MI 
or ischemic stroke). Information about cause-specific mortality and date of death was 
obtained through the established record linkage with ONS. Fatal MI and stroke were defined 
by primary cause of death (ICD-10 codes I21-I22 and I64 respectively). Patients were 
censored on the date of first ASCVD event. The pre-specified secondary endpoints were 
cardiovascular death (fatal MI or fatal ischemic stroke), hospitalization for heart failure and all-
cause mortality. Study approval was granted by the Independent Scientific Advisory 
Committee of the Medicines and Healthcare products Regulatory Agency. 
 Statistical analyses 
We defined clinical characteristics and outcome data both overall and according to risk 
groups (absence of microvascular disease at baseline, or stratified by the number of prevalent 
microvascular disease states). All reported P values are two-sided. Adjusted hazard ratios 
and corresponding 95% confidence intervals were estimated with Cox proportional-hazards 
models. Adjustment in all models was performed for age, gender, on treatment systolic and 
diastolic blood pressure, high- and low-density cholesterol, HbA1c, body-mass index, 
smoking status, index of multiple deprivation, antiplatelet, lipid-lowering and renin angiotensin 
blockade therapy. The group free of microvascular disease at baseline were used as the 
reference category. 
 
We assessed differences in predictive accuracy of a model including established risk factors 
from the Framingham risk function for a first CVD event (model A),20 and the same model 
incorporating microvascular disease variables (model B) for ASCVD events. Model 
discrimination was assessed with the use of the C-statistic.21 To evaluate the overall 
improvement in risk stratification with the addition of microvascular disease to fully adjusted 
models, we calculated net reclassification improvement statistic and the integrated-
discrimination-improvement statistic.22 Risk strata were as defined in the American College of 
Cardiology (ACC)/ American Heart Association (AHA) treatment guidelines for 10-year 
ASCVD risk (low-risk <5%, intermediate-risk 5-7.5%, and high-risk >7.5%)3 Statistical 
analyses were performed with the use of R software version 15.2.  
 
RESULTS 
 
Patient Characteristics 
Baseline characteristics of the study population, both overall and according to microvascular 
disease burden, are shown in Table 1. Individuals with microvascular disease were more 
likely to have an adverse cardiovascular risk profile with significantly greater levels of HbA1c 
and systolic blood pressure and worse renal function. Age and duration of diabetes 
significantly increased in a linear fashion with increasing burden of microvascular disease. 
Exceptions included a consistent trend for more favourable lipid parameters with increasing 
burden of microvascular disease, likely related to the greater use of lipid-lowering therapy. A 
comparison of the demographic characteristics of individuals with a single manifestation of 
microvascular disease versus those without is provided in the Supplementary Appendix 4. 
 
Primary and Secondary Outcome Measures 
Event rates of ASCVD per 1000 person years in those without microvascular disease were 
5.73 compared with 8.90, 9.14 and 11.63 among individuals with isolated retinopathy, 
nephropathy and peripheral neuropathy, respectively. Each microvascular disease state 
studied was significantly associated with ASCVD, and remained so following adjustment for 
established risk factors and after excluding individuals with multiple manifestations of 
microvascular disease (Table 5 in the Supplementary Appendix). Single manifestations of 
microvascular disease appear to confer at least as much risk as the failure to control 
conventional risk factor goals in adjusted analyses (Supplementary Appendix 6-8).  
 
Figure 1 shows the linear relationship between increasing burden of microvascular disease 
and ASCVD (Panel A), cardiovascular mortality (Panel B), and hospitalization for heart failure 
(Panel C), P for linear trend <0.001 for all. Analyses for all-cause mortality were qualitatively 
similar (Supplementary Appendix 9); we found a 3.9-fold excess risk of death from any cause 
among individuals with three manifestations of microvascular disease compared with none 
(Supplementary Appendix 10). Unadjusted event rates for ASCVD among individuals free of 
microvascular disease at baseline and among those with one, two, or three microvascular 
disease states were 5.7, 10.4, 15.5 and 22.5 per 1000 person years, respectively. After 
adjustment for potential confounders, the hazard ratios for ASCVD, cardiovascular death and 
hospitalization for heart failure remained significant but were attenuated across all three 
groups, suggesting that conventional risk factors account, in part, for the excess risk observed 
with cumulative burden of microvascular disease (Table 2).  
 
In fully adjusted models, a single manifestation of microvascular disease appears to as 
strongly associated with ASCVD as blood pressure, low-density cholesterol, glycated 
hemoglobin and smoking history (Figure 2). A similar relationship was observed for 
cardiovascular death, hospitalization for heart failure (Figure 2), and death from any cause 
(Supplementary Appendix 11). This association remained when established risk factors were 
dichotomised to reflect recommended risk factor goals and even when eGFR was included in 
models (Supplementary Appendix 12). When assessed across strata of risk factor control for 
HbA1c (<7.0%, and ≥7.0%), low-density cholesterol (<100, and ≥100 mg per decilitre) and 
blood pressure (<140/90, and ≥140/90 mm Hg), a consistent linear trend of greater risk of 
ASCVD with cumulative burden of microvascular disease and uncontrolled risk factors was 
observed (Figure 3).  
 
The addition of information on microvascular disease (model B) to a Cox model based on 
established risk factors included in the Framingham model (model A), yielded improvements 
in the C-statistic (0.715 versus 0.700, respectively) and integrated discrimination index (0.004, 
95% CI, 0.004-0.005, P<0.001). Across the three categories of ASCVD risk studied, the 
overall net reclassification improvement was 0.05 (95% CI, 0.04 to 0.06, P<0.001).  
 
DISCUSSION 
 
In a population cohort of individuals with type 2 diabetes, our findings show that burden of 
microvascular disease is a determinant of future cardiovascular risk. The risk of a first 
cardiovascular event increased linearly with the number of manifestations of microvascular 
disease present. Furthermore, the presence of isolated retinopathy, peripheral neuropathy, or 
nephropathy confer at least a similar risk of cardiovascular events as factors contained in 
contemporary risk equations such as blood pressure, low-density cholesterol and 
haemoglobin A1c. Despite significant differences in baseline values of glycated haemoglobin, 
low-density cholesterol and blood pressure among individuals with increasing burden of 
microvascular disease, these factors did not modify associations between microvascular 
disease and cardiovascular outcomes. We noted no deviations from linearity in subgroups 
stratified by varying degrees of risk factor control.  
 
Consistent with our findings, previous reports have documented an increase in cardiovascular 
risk with individual microvascular disease states.5-10 However, the true impact of 
microvascular disease may have been overestimated because risk ratios provided in the 
literature are subject to confounding by a lack of adjustment for the presence of disease in 
multiple microvascular beds. An important advance of this study was our ability to examine 
the effect of both cumulative burden, and isolated microvascular disease states on first 
presentation of cardiovascular disease. This approach was enabled by the routine collection 
of microvascular disease data in the UK, and the availability of electronic health record 
linkage.  
 
Although event rates in type 2 diabetes are falling and do not suggest a CHD risk equivalent 
as previously described,23, 24 lifetime risk remains high emphasizing the need to identify early 
markers of risk.25 At diagnosis of type 2 diabetes, the UK Prospective Diabetes Study 
identified retinopathy alone in 36% of participants.26 Currently, data recorded on the presence 
or absence of retinopathy, nephropathy and peripheral neuropathy are used in the UK to 
inform risk of developing blindness, renal failure, and amputation, respectively. Our findings 
suggest these data may offer a simple tool to identify very high-risk individuals with type 2 
diabetes who are currently perceived to be at lower absolute risk using contemporary risk 
models.  
 
Cardiovascular risk estimation in diabetes has important implications for primary prevention 
strategies. The 2013 ACC/ AHA guidelines on the control of blood cholesterol advocate 
moderate-intensity statin therapy in persons with diabetes who are 40-75 years of age; while 
high-intensity therapy is restricted to individuals with a ≥7.5% estimated 10-year risk of 
ASCVD.3 Our findings suggest that individuals with microvascular disease would be eligible 
for high-intensity statin treatment based on the recorded event rates. The 10-year risk of MI or 
ischemic stroke (fatal or non-fatal) in the present study was 10.4% in participants with a single 
manifestation of microvascular disease, 15.0% with two, and 22.5% with three microvascular 
beds affected. 
 
Among individuals with three manifestations of microvascular disease, our data indicate that 
good control of risk factors (HbA1c <7.0%, low-density cholesterol <100 per decilitre, and 
blood pressure <140/90) is associated with a halving of the risk of future cardiovascular 
events than when these factors are not at goal (17.4 versus 32.5 events per 1000 person 
years). Insights from the Steno-2 study support this observation that aggressive management 
of risk factors might mitigate some of the excess risk associated with microvascular disease.27 
It randomised patients with type 2 diabetes and persistent microalbuminuria to receive either 
intensive or conventional therapy for a number of modifiable risk factors including glucose 
control, blood pressure, total cholesterol and triglyceride levels. Intensive therapy was 
associated with a lower risk of both fatal and non-fatal cardiovascular events at a median 
follow-up of 13 years. An important caveat however is that baseline cardiovascular risk factors 
were significantly more adverse in Steno-2 compared to the present cohort.  
 
We also assessed the associations of microvascular disease burden with hospitalization for 
heart failure and report event rates around half those observed in the recent Reduction of 
Atherothrombosis for Continued Health (REACH) registry.28 Among participants with 
established atherothrombosis and a prior ischemic event enrolled in REACH, 6.5% of patients 
were hospitalized for heart failure corresponding to a rate of 16 per 1000 person years. This 
compared to an overall rate of 6 per 1000 person years in this study of individuals free of 
cardiovascular disease at baseline. Those with disease in three microvascular beds were at 
significantly greater risk, with event rates of 15 per 1000 person years, similar to those with a 
history of MI or stroke in REACH. In comparison with diabetic patients free from 
microvascular disease, the adjusted hazards for heart failure with the presence of one, two, or 
three microvascular disease states were 1.53, 2.16, and 3.02, respectively. The mechanisms 
behind this association are unclear but plausible contributors include CAN, which frequently 
co-exists with other microvascular disease states,29 and may be the diabetes-specific process 
that explains part of the excess risk of heart failure not accounted for by increased burden of 
atherothrombosis.30, 31 
 
While the present data derive from a validated and nationally representative sample of 
England, results should not be extrapolated to dissimilar populations. Important limitations of 
the study include our reliance on comprehensive code lists for any given baseline or outcome 
variable. This is a limitation common to all studies using routinely recorded data and was 
mitigated through the use of a validated approach for defining baseline and outcome 
parameters.16, 19 Analyses were restricted to individuals in whom complete information was 
available on prevalent microvascular disease and may be subject to selection bias. 
Examination of the association between microvascular disease and ASCVD among 
individuals with data missing on all three diseases showed no qualitative difference with the 
complete cohort (Supplementary Appendix 13). Results may have been affected by 
unmeasured variables such as diet, which was not considered in our analyses because these 
data are unreliably recorded. Finally, the data presented here are observational in nature and 
although attempts have been made to reduce confounding by statistical adjustment we 
cannot exclude the possibility of residual confounding as part of the explanation for our 
findings. 
 
In this linked primary and secondary care study of diabetic adults, microvascular disease was 
found to confer a risk equivalent to conventional factors including smoking, hypertension and 
dyslipidaemia. Cardiovascular risk increased with the total number of microvascular beds 
affected, suggesting a continued broad assessment program for retinopathy, nephropathy 
and peripheral neuropathy can provide reliable information on cardiovascular risk, in addition 
to morbidity linked to individual microvascular disease states. Such prognostic data has 
implications for cardiovascular risk stratification and prevention strategies. 
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Table 1. Baseline Characteristics 
 
 
Number microvascular disease states† All  
n=48 367 
 
0 
n=16 280 
1 
n=19 125 
2 
n=10 184 
3 
n=2778 
 
Age, years 64.8 (11.7)*** 69.3 (11.7) 72.0 (11.0) 72.2 (10.7) 68.5 (11.9) 
Women 7826 (48.1)*** 8637 (45.2) 4284 (42.1) 1083 (40.0) 21830 (45.1) 
White ethnicity 4184 (91.0)*** 4776 (90.3) 2450 (90.8) 618 (89.4) 12028 (90.6) 
BMI, kg/m2 30.8 (6.2)*** 30.6 (6.4) 30.5 (6.2) 30.7 (6.2) 30.7 (6.3) 
HbA1c, % 7.18 (1.23)*** 7.28 (1.29) 7.45 (1.38) 7.87 (1.57) 7.31 (1.32) 
Duration diabetes, years 5.8 (4.5)*** 7.7 (5.8) 10.3 (7.0) 14.5 (8.1) 8.0 (6.3) 
Systolic blood pressure, mmHg 135.6 (12.8)*** 137.1 (13.3) 138.2 (14.5) 139.7 (15.2) 137.0 (13.6) 
Diastolic blood pressure, mmHg 77.4 (7.8)*** 76.2 (8.1) 74.7 (8.5) 74.0 (8.7) 76.2 (8.2) 
Total cholesterol, mmol/L 4.36 (0.90)*** 4.28 (0.89) 4.20 (0.89) 4.13 (1.00) 4.28 (0.91) 
HDL cholesterol, mmol/L 1.28 (0.36)*** 1.27 (0.39) 1.25 (0.39) 1.20 (0.38) 1.26 (0.38) 
LDL cholesterol, mmol/L 2.37 (0.86)*** 2.29 (0.83) 2.22 (0.82) 2.17 (0.84) 2.29 (0.84) 
eGFR, mL/min/1.73m2 75.6 (19.6)*** 70.9 (22.6) 64.9 (24.1) 56.9 (23.7) 70.5 (22.6) 
Smoking history 11812 (72.6)*** 14575 (76.2) 7941 (78.0) 2242 (80.7) 36570 (75.8) 
Deprivation index ≤ 5th decile 5898 (54.2)*** 7058 (53.6) 3765 (53.6) 1001 (51.4) 17722 (53.7) 
Statin use  11472 (70.5)*** 13875 (72.5) 7655 (75.2) 2094 (75.4) 35096 (72.6) 
ACEi/ARB 10312 (63.3)*** 14301 (74.8) 8645 (84.9) 2587 (93.1) 35845 (74.1) 
Antiplatelet 9273 (57.0)*** 12467 (65.2) 7265 (71.3) 2091 (75.3) 31096 (64.3) 
† Microvascular diseases considered include retinopathy, nephropathy and peripheral neuropathy. Data are mean 
(SD) or number (%). BMI indicates body mass index; HbA1c, glycosylated haemoglobin; HDL, high-density 
lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; ACEi/ARB, angiotensin 
converting enzyme inhibitor/ angiotensin receptor blocker. *P<0.05; **P<0.01; ***P<0.001. P values from Chi square 
test or ANOVA are provided for the overall trend with increasing number of microvascular disease states. Missing 
values: The following variables had missing values: Ethnicity (n=35095, 72.6%), BMI (n=82, 0.2%), HbA1c (n=101, 
0.2%), Systolic BP (n=15, 0.03%), Diastolic BP (n=15, 0.03%), Total cholesterol (n=38, 0.08%), HDL cholesterol 
(n=3825, 7.9%), LDL cholesterol (n=8311, 17.2%), eGFR (n=1752, 3.6%), Smoking status (n=123, 0.3%), 
Deprivation index (n=.15255, 46.5%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Adjusted Hazard ratios of Clinical Outcomes by Burden of Microvascular 
Disease* 
 
 Number microvascular disease states 
 
0 
n=16 280 
1 
n=19 125 
2 
n=10 184 
3 
n=2778 
Atherosclerotic cardiovascular disease     
    N 528 (3.2%) 1064 (5.6%) 799 (7.9%) 298 (10.7%) 
    Event rate per 1000 person years 5.73 10.37 15.45 22.50 
    Unadjusted hazard ratio 1.00 1.83 (1.64-2.03) 2.75 (2.46-3.06) 4.03 (3.50-4.65) 
    Adjusted hazard ratio (95% CI)* 1.00 1.30 (1.16-1.47) 1.64 (1.45-1.87) 2.24 (1.91-2.64) 
Hospitalization for heart failure     
    N 199 (1.2%) 496 (2.6%) 474 (4.7%) 188 (6.8%) 
    Event rate per 1000 person years 2.35 5.26 10.01 15.51 
    Unadjusted hazard ratio 1.00 2.24 (1.90-2.64) 4.26 (3.61-5.03) 6.61 (5.42-8.07) 
    Adjusted hazard ratio (95% CI)* 1.00 1.53 (1.28-1.82) 2.16 (1.81-2.59) 3.02 (2.43-3.75) 
Cardiovascular mortality     
    n 145 (1.9%) 346 (4.0%) 277 (6.2%) 131 (11.5%) 
    Event rate per 1000 person years 1.86 3.97 6.24 11.46 
    Unadjusted hazard ratio 1.00 2.13 (1.75-2.58) 3.35 (2.74-4.10) 6.16 (4.86-7.80) 
    Adjusted hazard ratio (95% CI)* 1.00 1.39 (1.14-1.71) 1.73 (1.40-2.16) 2.87 (2.21-3.72) 
* Adjusted for age, gender, systolic BP, diastolic BP, LDL-C, HDL-C, HbA1c, BMI, CKD, smoking status, index of 
multiple deprivation, antiplatelet therapy, lipid-lowering and renin angiotensin blockade treatment 
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Figure 1.  Unadjusted freedom from cardiovascular events (A), hospitalization for heart 
failure (B), and cardiovascular mortality (C) by cumulative burden of microvascular 
disease.  
Cardiovascular events defined as fatal and non-fatal events of myocardial infarction or stroke. Log-rank test for the 
linear association between cumulative burden of microvascular disease for cardiovascular events p<0.001; and for 
all-cause mortality p<0.001. 
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Figure 2.  Adjusted hazard ratio for cardiovascular events (A), hospitalization for heart 
failure (B), and cardiovascular mortality (C) by cumulative burden of microvascular 
disease and per 1 SD difference in values for established risk factors* 
Cardiovascular events defined as first fatal or non-fatal event of myocardial infarction or stroke; cardiovascular death 
as first fatal myocardial infarction or stroke. A 1 SD increase from the mean for each established risk factor is: BP 
>150.6/84.4; LDL >121.0; BMI>36.9 kg/m2; HbA1c >8.6%. 
Adjusted for age, gender, systolic BP, diastolic BP, LDL-C, HDL-C, HbA1c, smoking status, index of multiple 
deprivation, antiplatelet therapy, lipid-lowering and renin angiotensin blockade treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Adjusted cardiovascular event rates by cumulative burden of microvascular 
disease and established risk factor goals* 
Cardiovascular events defined as fatal and non-fatal events of myocardial infarction or stroke.  
To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. 
*Adjusted for age, gender, systolic BP, diastolic BP, LDL-C, HDL-C, HbA1c, smoking status, index of multiple 
deprivation, antiplatelet therapy, lipid-lowering and renin angiotensin blockade treatment 
 
